[144] Oculis Holding AG SEC Filing
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Oculis Holding AG presenta una notifica di vendita proposta di 25,000 azioni ordinarie tramite UBS Financial Services il 23/09/2025, con un valore di mercato aggregato di $442,500 secondo l'avviso. La pratica riporta 43,662,402 azioni ordinarie in circolazione. Le azioni sono state acquisite il 02/03/2023, come emissione di azioni di earnout dall'emittente e interamente pagate in tale data. Il deposito riporta nessuna vendita di titoli dell'emittente negli ultimi tre mesi e include la dichiarazione standard secondo cui il venditore non è a conoscenza di alcuna informazione avversa materiale non divulgata.
Oculis Holding AG presenta un informe de venta propuesta de 25,000 acciones ordinarias a través de UBS Financial Services el 23/09/2025, con un valor de mercado agregado de $442,500 según el aviso. El archivo muestra 43,662,402 acciones en circulación. Las acciones fueron adquiridas el 02/03/2023 como emisión de acciones de earnout por parte del emisor y pagadas en su totalidad en dicha fecha. El presentante informa no haber realizado ventas de valores del emisor en los últimos tres meses e incluye la declaración estándar de que el vendedor no tiene conocimiento de ninguna información adversa material no divulgada.
Oculis Holding AG는 UBS Financial Services를 통해 25,000주의 보통주 매각 제안을 2025/09/23에 제출했으며, 공지에 따라 총 시장가치는 $442,500이다. 제출 서류에는 주식이 43,662,402주 발행 주식으로 기재되어 있다. 이 주식은 2023/03/02에 발행인으로부터의 이익 분배 주식으로 취득되었으며 그 날짜에 전액 납입되었다. 제출자는 지난 3개월 동안 발행인의 증권 매매가 없었음을 보고하며, 공개되지 않은 중요한 악재 정보가 없다는 표준 진술을 포함한다.
Oculis Holding AG dépose une notification de vente proposée de 25 000 actions ordinaires via UBS Financial Services le 23/09/2025, pour une valeur marchande totale de $442 500 selon l'avis. Le dossier indique 43 662 402 actions ordinaires en circulation. Les actions ont été acquises le 02/03/2023 en tant qu'émission d'actions de earnout par l'émetteur et entièrement payées à cette date. Le déposant déclare qu'il n'a effectué aucune vente de valeurs mobilières de l'émetteur au cours des trois derniers mois et inclut la déclaration standard selon laquelle le vendeur n'est au courant d'aucune information défavorable importante non divulguée.
Oculis Holding AG reicht eine Meldung über einen geplanten Verkauf von 25.000 Stammaktien über UBS Financial Services am 23.09.2025 ein, mit einem Gesamtmarktwert von $442,500 gemäß dem Hinweis. Die Einreichung weist 43.662.402 ausstehende Aktien aus. Die Aktien wurden am 02.03.2023 als Emission von Earnout-Aktien vom Emittenten erworben und an diesem Datum vollständig bezahlt. Der Einreicher meldet, dass in den letzten drei Monaten keine Verkäufe von Wertpapieren des Emittenten getätigt wurden, und schließt die Standarderklärung ein, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen verfügt.
تقدّم Oculis Holding AG تقريراً عن بيع مقترح لـ 25,000 سهماً عادياً عبر UBS Financial Services في 23/09/2025، بقيمة سوقية إجمالية قدرها $442,500 وفقاً للإشعار. يعرض الملف 43,662,402 سهماً قائماً. تم الحصول على الأسهم في 02/03/2023 كإصدار أسهم مكافأة من المُصدر وتم سدادها بالكامل في ذلك التاريخ. يفيد المُقدِّم بأنه لم يجرِ أي مبيعات لأسهم المُصدر خلال الأشهر الثلاثة الماضية ويتضمّن البيان القياسي بأن البائع غير مطّلع على أي معلومات سلبية جوهرية غير مكشوفة.
Oculis Holding AG 提交通过 UBS Financial Services 于 2025/09/23 提出的出售提议，涉及 25,000 股普通股，按照通知，市场总值为 $442,500。申报显示在外流通股为 43,662,402 股。这些股份于 2023/03/02 作为发行人发出的业绩对价股份获得，并在该日全额支付。申报人报告在过去三个月内未有发行人证券的销售，并包含标准声明，卖方对任何未披露的重要负面信息并不知情。
- Timely, specific disclosure of broker, planned sale date, share count and aggregate market value
- Securities were acquired as earnout shares, indicating they originated from the issuer rather than an external purchase
- None.
Insights
TL;DR: Routine insider sale notice: 25,000 shares (~$442.5k) from earnout grant; no recent sales reported.
The Form 144 documents a planned sale via UBS of 25,000 common shares acquired as earnout shares on 03/02/2023. The filing provides key transactional details—broker, planned sale date, aggregate value and outstanding share count—enabling investors to quantify the potential near-term supply impact. No securities sold in the prior three months is disclosed, which limits immediate trend indications. This filing appears procedural and provides necessary transparency but does not in itself change fundamentals.
TL;DR: Compliance-focused disclosure showing an insider monetizing earnout shares; standard attestation included.
The notice meets Rule 144 disclosure norms by naming the executing broker, planned sale date and acquisition provenance (earnout issuance). The attestation that the seller lacks undisclosed material information is present, and there are no reported sales in the prior three months. From a governance perspective, this is a routine, compliant disclosure of an executive/insider monetization event rather than a material corporate action.
Oculis Holding AG presenta una notifica di vendita proposta di 25,000 azioni ordinarie tramite UBS Financial Services il 23/09/2025, con un valore di mercato aggregato di $442,500 secondo l'avviso. La pratica riporta 43,662,402 azioni ordinarie in circolazione. Le azioni sono state acquisite il 02/03/2023, come emissione di azioni di earnout dall'emittente e interamente pagate in tale data. Il deposito riporta nessuna vendita di titoli dell'emittente negli ultimi tre mesi e include la dichiarazione standard secondo cui il venditore non è a conoscenza di alcuna informazione avversa materiale non divulgata.
Oculis Holding AG presenta un informe de venta propuesta de 25,000 acciones ordinarias a través de UBS Financial Services el 23/09/2025, con un valor de mercado agregado de $442,500 según el aviso. El archivo muestra 43,662,402 acciones en circulación. Las acciones fueron adquiridas el 02/03/2023 como emisión de acciones de earnout por parte del emisor y pagadas en su totalidad en dicha fecha. El presentante informa no haber realizado ventas de valores del emisor en los últimos tres meses e incluye la declaración estándar de que el vendedor no tiene conocimiento de ninguna información adversa material no divulgada.
Oculis Holding AG는 UBS Financial Services를 통해 25,000주의 보통주 매각 제안을 2025/09/23에 제출했으며, 공지에 따라 총 시장가치는 $442,500이다. 제출 서류에는 주식이 43,662,402주 발행 주식으로 기재되어 있다. 이 주식은 2023/03/02에 발행인으로부터의 이익 분배 주식으로 취득되었으며 그 날짜에 전액 납입되었다. 제출자는 지난 3개월 동안 발행인의 증권 매매가 없었음을 보고하며, 공개되지 않은 중요한 악재 정보가 없다는 표준 진술을 포함한다.
Oculis Holding AG dépose une notification de vente proposée de 25 000 actions ordinaires via UBS Financial Services le 23/09/2025, pour une valeur marchande totale de $442 500 selon l'avis. Le dossier indique 43 662 402 actions ordinaires en circulation. Les actions ont été acquises le 02/03/2023 en tant qu'émission d'actions de earnout par l'émetteur et entièrement payées à cette date. Le déposant déclare qu'il n'a effectué aucune vente de valeurs mobilières de l'émetteur au cours des trois derniers mois et inclut la déclaration standard selon laquelle le vendeur n'est au courant d'aucune information défavorable importante non divulguée.
Oculis Holding AG reicht eine Meldung über einen geplanten Verkauf von 25.000 Stammaktien über UBS Financial Services am 23.09.2025 ein, mit einem Gesamtmarktwert von $442,500 gemäß dem Hinweis. Die Einreichung weist 43.662.402 ausstehende Aktien aus. Die Aktien wurden am 02.03.2023 als Emission von Earnout-Aktien vom Emittenten erworben und an diesem Datum vollständig bezahlt. Der Einreicher meldet, dass in den letzten drei Monaten keine Verkäufe von Wertpapieren des Emittenten getätigt wurden, und schließt die Standarderklärung ein, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen verfügt.
FAQ
What does OCSAW's Form 144 report?
When and how were the shares being sold acquired?
How many Oculis Holding AG shares are outstanding per the filing?
Were any issuer securities sold by the filer in the past three months?
Who is the broker handling the proposed sale?
